Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kestra Medical TechnologiesKMTS -2.27%12 Net Cash per Share is $1.67 as of Apr. 2026, which is 84% below its 10-year median of 10.40. GuruFocus rates KMTS with a GF Score™ of 12/100. The stock has 5 warning signs investors should review. Among 300 Medical Devices & Instruments companies, Kestra Medical Technologies ranks worse than 64.33% on this metric.
The historical rank and industry rank for Kestra Medical Technologies's Net Cash per Share or its related term are showing as below:
KMTS'
s Price-to-Net-Cash Range Over the Past 10 Years
Min: 8.38 Med: 10.4 Max: 12.6
Current: 12.6
During the past 6 years, the highest Price-to-Net-Cash Ratio of Kestra Medical Technologies was 12.60. The lowest was 8.38. And the median was 10.40.
KMTS's Price-to-Net-Cash is ranked worse than 64.33% of 300
companies
in the Medical Devices & Instruments industry
Industry Median: 7.555
vs KMTS: 12.60
Kestra Medical Technologies (NAS:KMTS) Net Cash per Share Explanation
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
Kestra Medical Technologies Net Cash per Share Related Terms
Kestra Medical Technologies Net Cash per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kestra Medical Technologies Net Cash per Share Chart
KMTS vs ATRC, STAA, BLFS: Net Cash per Share Comparison
For the Medical Instruments & Supplies subindustry, Kestra Medical Technologies's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kestra Medical Technologies Price-to-Net-Cash vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Kestra Medical Technologies's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where Kestra Medical Technologies's Price-to-Net-Cash falls into.
Kestra Medical Technologies Net Cash per Share Calculation
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
Kestra Medical Technologies's Net Cash per Share for the fiscal year that ended in Apr. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kestra Medical Technologies (KMTS) has a Net Cash per Share of $1.67 as of Apr. 2026. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Kestra Medical Technologies and its competitors. This is 84% below median its historical median of 10.40. Over the past decade, Kestra Medical Technologies' Net Cash per Share has ranged from 8.38 to 12.60. According to the industry distribution chart, Kestra Medical Technologies ranks #193 out of 300 companies in the Medical Devices & Instruments industry, placing it in the top 64.3%.
Is Kestra Medical Technologies' Net Cash per Share too high?
Kestra Medical Technologies' current Net Cash per Share of $1.67 is 84% below median its 10-year median of 10.40. Over the past 10 years, this metric has ranged from a low of 8.38 to a high of 12.60. The Medical Devices & Instruments industry median Net Cash per Share is 7.56. Kestra Medical Technologies' value of $1.67 is 77.9% below this industry median. Based on the distribution chart, Kestra Medical Technologies ranks #193 out of 300 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Kestra Medical Technologies has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Kestra Medical Technologies' Net Cash per Share compare to ATRC and STAA?
According to the Medical Devices & Instruments industry distribution chart, Kestra Medical Technologies ranks #193 out of 300 companies for Net Cash per Share. This places Kestra Medical Technologies in the lower half of its industry. The industry median Net Cash per Share is 7.56. Kestra Medical Technologies' value of $1.67 is 77.9% below this benchmark. Historically, Kestra Medical Technologies' own Net Cash per Share has ranged from 8.38 to 12.60 over the past decade. While the company's 10-year median is 10.40 vs. the industry median of 7.56, Kestra Medical Technologies has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Cash per Share for a Medical Devices & Instruments company?
The median Net Cash per Share among Medical Devices & Instruments companies is 7.56, based on 300 companies in the industry. Companies in the top quartile (top 25%) have a Net Cash per Share significantly above this median, while those in the bottom quartile fall well below. However, Net Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kestra Medical Technologies's current Net Cash per Share of $1.67 is 77.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Cash per Share mean?
A high Net Cash per Share can signal that a stock is expensive relative to its fundamentals. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Kestra Medical Technologies and its competitors. For the Medical Devices & Instruments industry, the median Net Cash per Share is 7.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kestra Medical Technologies's current Net Cash per Share is $1.67, which is 84% below median its own 10-year median of 10.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kestra Medical Technologies stock overvalued right now?
Kestra Medical Technologies (KMTS) has a current Net Cash per Share of $1.67. The current Net Cash per Share is $1.67, which is 84% below median its 10-year median of 10.40 and 77.9% below the Medical Devices & Instruments industry median of 7.56. Kestra Medical Technologies' overall GF Score™ is 12/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Cash per Share calculated?
Net Cash per Share is calculated from a company's financial statements. For Kestra Medical Technologies (KMTS), the current Net Cash per Share is $1.67 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Kestra Medical Technologies Ltd is a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. It has developed and is commercializing its Cardiac Recovery System platform, a comprehensive and developed system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of its Cardiac Recovery System platform is the ASSURE WCD, a next-generation wearable cardioverter defibrillator (WCD) used to protect patients at an elevated risk of sudden cardiac arrest (SCA), a prominent public health problem.
12GF Score
Get the complete analysis for KMTS
Net Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KMTS has been successfully added to your 
